17607 Gold Plaza, Omaha, NE
402-991-8468
Patient Portal
Menu

News

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer

May 21, 2020

Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

View Article

FDA Approves First Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer

April 16, 2020

“This is the first approval specifically for patients with low-grade UTUC and provides an option for some patients who may otherwise require a nephroureterectomy,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, in a statement.

View Article

Low-Effort Eats

January 15, 2020

WHEN YOU’RE EXHAUSTED FROM CHEMOTHERAPY, the daily task of preparing three square meals or even just dinner may seem like an insurmountable hurdle. But maintaining a good diet is essential during treatment.

View Article

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer

January 9, 2020

On January 8, 2020, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

View Article

Real-World Outcomes of Sipuleucel-T Treatment in PROCEED, a Prospective Registry of Men With Metastatic Castration-Resistant Prostate Cancer

December 17, 2019

Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase 3 trial Immunotherapy for Prostate Adenocarcinoma Treatment, sipuleucel-T significantly reduced the risk of death among patients with mCRPC and improved median overall survival (OS) by 4.1 months versus a placebo.1 Sipuleucel-T is recommended

Download Article